Weight & metabolic liver research
Survodutide vs Mazdutide
Both are GLP-1/glucagon dual agonists; compare obesity evidence, liver endpoints, populations, doses and regulatory stage.
At a glance
Survodutide
Mazdutide
Human evidence
Randomized Phase 2 studies show dose-dependent weight loss in obesity and histologic MASH improvement without fibrosis worsening. Phase 3 development is ongoing.
Phase 3 GLORY trials show substantial weight loss in Chinese adults. Mazdutide received its first approval in China in June 2025 for long-term weight management and later for type 2 diabetes.
Research focus
Obesity, MASH, liver fibrosis, cardiovascular outcomes
Obesity, type 2 diabetes, metabolic liver disease, obstructive sleep apnoea
Regulatory status
Investigational; no general marketing authorisation for obesity or MASH identified in the reviewed jurisdictions.
First approved in China in June 2025 for chronic weight management in qualifying adults; later approved there for glycaemic control in type 2 diabetes. Not a globally authorised medicine.
Route / formulation
Evidence is from trial-grade once-weekly subcutaneous product with protocol-driven escalation.
Clinical evidence concerns regulated trial/authorised subcutaneous formulations. Research-market material cannot be assumed equivalent.
No direct head-to-head trial identified Both are GLP-1/glucagon dual agonists; compare obesity evidence, liver endpoints, populations, doses and regulatory stage.